Endometrial Cancer | Topics

High Tumor Mutational Burden Associated with High Responses to Dostarlimab Monotherapy for Endometrial Cancer
September 16, 2021

Investigators identified a link between high tumor mutational burden and high responses to dostarlimab among patients with endometrial cancer.

FDA Grants Full Approval For Lenvatinib and Pembrolizumab Combination in Advanced dMMR/MSI-H Endometrial Cancer
July 22, 2021

Phase 3 results demonstrating the superiority of the pembrolizumab plus lenvatinib combination vs standard chemotherapy served as a confirmatory trial for its approval in certain patients with advanced endometrial cancer.

PD-1 Inhibitor Dostarlimab Earns Accelerated Approval in Mismatch Repair Deficient Endometrial Cancer
April 22, 2021

Based on results from the phase 2 GARNET trial, dostarlimab may be used to treat recurrent or advanced endometrial cancer progressing on or after treatment with a platinum-containing chemotherapy that is mismatch repair deficient.